Exact Mass: 171.14973039999998
Exact Mass Matches: 171.14973039999998
Found 283 metabolites which its exact mass value is equals to given mass value 171.14973039999998
,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Gabapentin
Gabapentin was originally developed as a chemical analogue of gamma-aminobutyric acid (GABA) to reduce the spinal reflex for the treatment of spasticity and was found to have anticonvulsant activity in various seizure models. In addition, it also displays antinociceptive activity in various animal pain models. Clinically, gabapentin is indicated as an add-on medication for the treatment of partial seizures, and neuropathic pain. It was also claimed to be beneficial in several other clinical disorders such as anxiety, bipolar disorder, and hot flashes. The possible mechanisms or targets involved in the multiple therapeutic actions of gabapentin have been actively studied. Since gabapentin was developed, several hypotheses had been proposed for its action mechanisms. They include selectively activating the heterodimeric GABA(B) receptors consisting of GABA(B1a) and GABA(B2) subunits, selectively enhancing the NMDA current at GABAergic interneurons, or blocking AMPA-receptor-mediated transmission in the spinal cord, binding to the L-alpha-amino acid transporter, activating ATP-sensitive K(+) channels, activating hyperpolarization-activated cation channels, and modulating Ca(2+) current by selectively binding to the specific binding site of [(3)H]gabapentin, the alpha(2)delta subunit of voltage-dependent Ca(2+) channels. Different mechanisms might be involved in different therapeutic actions of gabapentin. In this review, we summarized the recent progress in the findings proposed for the antinociceptive action mechanisms of gabapentin and suggest that the alpha(2)delta subunit of spinal N-type Ca(2+) channels is very likely the analgesic action target of gabapentin. (PMID: 16474201) [HMDB] Gabapentin was originally developed as a chemical analogue of gamma-aminobutyric acid (GABA) to reduce the spinal reflex for the treatment of spasticity and was found to have anticonvulsant activity in various seizure models. In addition, it also displays antinociceptive activity in various animal pain models. Clinically, gabapentin is indicated as an add-on medication for the treatment of partial seizures, and neuropathic pain. It was also claimed to be beneficial in several other clinical disorders such as anxiety, bipolar disorder, and hot flashes. The possible mechanisms or targets involved in the multiple therapeutic actions of gabapentin have been actively studied. Since gabapentin was developed, several hypotheses had been proposed for its action mechanisms. They include selectively activating the heterodimeric GABA(B) receptors consisting of GABA(B1a) and GABA(B2) subunits, selectively enhancing the NMDA current at GABAergic interneurons, or blocking AMPA-receptor-mediated transmission in the spinal cord, binding to the L-alpha-amino acid transporter, activating ATP-sensitive K(+) channels, activating hyperpolarization-activated cation channels, and modulating Ca(2+) current by selectively binding to the specific binding site of [(3)H]gabapentin, the alpha(2)delta subunit of voltage-dependent Ca(2+) channels. Different mechanisms might be involved in different therapeutic actions of gabapentin. In this review, we summarized the recent progress in the findings proposed for the antinociceptive action mechanisms of gabapentin and suggest that the alpha(2)delta subunit of spinal N-type Ca(2+) channels is very likely the analgesic action target of gabapentin. (PMID: 16474201). D018377 - Neurotransmitter Agents > D018683 - Excitatory Amino Acid Agents > D018691 - Excitatory Amino Acid Antagonists D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D014151 - Anti-Anxiety Agents D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D018692 - Antimanic Agents N - Nervous system > N02 - Analgesics > N02B - Other analgesics and antipyretics > N02BF - Gabapentinoids D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents C78272 - Agent Affecting Nervous System > C29756 - Sedative and Hypnotic D002491 - Central Nervous System Agents > D000927 - Anticonvulsants D002491 - Central Nervous System Agents > D000700 - Analgesics
8-(Methylthio)octanenitrile
8-(Methylthio)octanenitrile is found in green vegetables. 8-(Methylthio)octanenitrile is isolated from watercress (Nasturtium officinale). Isolated from watercress (Nasturtium officinale). 8-(Methylthio)octanenitrile is found in green vegetables.
Rasagiline
Rasagiline is only found in individuals that have used or taken this drug. It is an irreversible inhibitor of monoamine oxidase and is used as a monotherapy in early Parkinsons disease or as an adjunct therapy in more advanced cases.The precise mechanisms of action of rasagiline is unknown. One mechanism is believed to be related to its MAO-B inhibitory activity, which causes an increase in extracellular levels of dopamine in the striatum. The elevated dopamine level and subsequent increased dopaminergic activity are likely to mediate rasagilines beneficial effects seen in models of dopaminergic motor dysfunction. N - Nervous system > N04 - Anti-parkinson drugs > N04B - Dopaminergic agents > N04BD - Monoamine oxidase b inhibitors D002491 - Central Nervous System Agents > D018696 - Neuroprotective Agents C78272 - Agent Affecting Nervous System > C38149 - Antiparkinsonian Agent D004791 - Enzyme Inhibitors > D008996 - Monoamine Oxidase Inhibitors C471 - Enzyme Inhibitor > C667 - Monoamine Oxidase Inhibitor D020011 - Protective Agents
N,2,3-Trimethyl-2-(1-methylethyl)butanamide
N,2,3-Trimethyl-2-(1-methylethyl)butanamide is a physiological stem cooling agent used in food; its effect is similar to that of menthol but without the strong minty flavour. N,2,3-Trimethyl-2-(1-methylethyl)butanamide is a flavouring agent for chewing gum and candie Physiol. stem cooling agent used in food; its effect is similar to that of menthol but without the strong minty flavour. Flavouring agent for chewing gum and candies
2,5-Dihydro-4,5-dimethyl-2-(2-methylpropyl)thiazole
2,5-Dihydro-4,5-dimethyl-2-(2-methylpropyl)thiazole is found in animal foods. 2,5-Dihydro-4,5-dimethyl-2-(2-methylpropyl)thiazole is a component of cooked beef aroma. 2,5-Dihydro-4,5-dimethyl-2-(2-methylpropyl)thiazole is a flavouring ingredient. Component of cooked beef aroma. Flavouring ingredient. 2,5-Dihydro-4,5-dimethyl-2-(2-methylpropyl)thiazole is found in animal foods.
2,5-Dihydro-4,5-dimethyl-2-(1-methylpropyl)thiazole
2,5-Dihydro-4,5-dimethyl-2-(1-methylpropyl)thiazole is a flavouring ingredient. 2,5-Dihydro-4,5-dimethyl-2-(1-methylpropyl)thiazole is reported in hydrolysed vegetable protein. Flavouring ingredient. Reported in hydrolysed vegetable protein
1-Hydroxy-2,2,6,6-tetramethyl-4-piperidinone
1-Methyl-4-phenyl-2H-pyridine
D010575 - Pesticides > D006540 - Herbicides D016573 - Agrochemicals
Moroxydine
J - Antiinfectives for systemic use > J05 - Antivirals for systemic use > J05A - Direct acting antivirals D000890 - Anti-Infective Agents > D000998 - Antiviral Agents D007004 - Hypoglycemic Agents > D001645 - Biguanides C254 - Anti-Infective Agent > C281 - Antiviral Agent
gabapentin
D018377 - Neurotransmitter Agents > D018683 - Excitatory Amino Acid Agents > D018691 - Excitatory Amino Acid Antagonists D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D014151 - Anti-Anxiety Agents D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D018692 - Antimanic Agents N - Nervous system > N02 - Analgesics > N02B - Other analgesics and antipyretics > N02BF - Gabapentinoids D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents C78272 - Agent Affecting Nervous System > C29756 - Sedative and Hypnotic D002491 - Central Nervous System Agents > D000927 - Anticonvulsants D002491 - Central Nervous System Agents > D000700 - Analgesics CONFIDENCE standard compound; EAWAG_UCHEM_ID 2561
Moroxydine
J - Antiinfectives for systemic use > J05 - Antivirals for systemic use > J05A - Direct acting antivirals D000890 - Anti-Infective Agents > D000998 - Antiviral Agents D007004 - Hypoglycemic Agents > D001645 - Biguanides C254 - Anti-Infective Agent > C281 - Antiviral Agent relative retention time with respect to 9-anthracene Carboxylic Acid is 0.052 relative retention time with respect to 9-anthracene Carboxylic Acid is 0.050 relative retention time with respect to 9-anthracene Carboxylic Acid is 0.053
gabapentin
D018377 - Neurotransmitter Agents > D018683 - Excitatory Amino Acid Agents > D018691 - Excitatory Amino Acid Antagonists D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D014151 - Anti-Anxiety Agents D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D018692 - Antimanic Agents N - Nervous system > N02 - Analgesics > N02B - Other analgesics and antipyretics > N02BF - Gabapentinoids D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents C78272 - Agent Affecting Nervous System > C29756 - Sedative and Hypnotic D002491 - Central Nervous System Agents > D000927 - Anticonvulsants D002491 - Central Nervous System Agents > D000700 - Analgesics CONFIDENCE standard compound; INTERNAL_ID 1678 CONFIDENCE standard compound; INTERNAL_ID 4114 CONFIDENCE Reference Standard (Level 1)
Rasagiline
N - Nervous system > N04 - Anti-parkinson drugs > N04B - Dopaminergic agents > N04BD - Monoamine oxidase b inhibitors D002491 - Central Nervous System Agents > D018696 - Neuroprotective Agents C78272 - Agent Affecting Nervous System > C38149 - Antiparkinsonian Agent D004791 - Enzyme Inhibitors > D008996 - Monoamine Oxidase Inhibitors C471 - Enzyme Inhibitor > C667 - Monoamine Oxidase Inhibitor D020011 - Protective Agents
2-Methyl-2-propanyl cis-3-aminocyclobutanecarboxylate
Cyclohexanecarboxylic acid, 2-amino-, ethyl ester, (1S,2R)-
1-Piperazineethanamine,-alpha-,-alpha-,4-trimethyl-(9CI)
5-CHLORO-4-(4,4,5,5-TETRAMETHYL-[1,3,2]DIOXABOROLAN-2-YL)-1-TRIISOPROPYLSILANYL-1H-PYRROLO[2,3-B]PYRIDINE
4-(4,5-DIHYDRO-1 H-IMIDAZOL-2-YLAMINO)-BUTYRIC ACID
C7H13N3O2 (171.10077180000002)
(r)-(-)-n-methyl-1-phenyl-2-(1-pyrrolidino)ethylamine
Iproheptine
C308 - Immunotherapeutic Agent > C29578 - Histamine-1 Receptor Antagonist
N-Propargyl-1(S)-aminoindan
D002491 - Central Nervous System Agents > D018696 - Neuroprotective Agents D004791 - Enzyme Inhibitors > D008996 - Monoamine Oxidase Inhibitors D020011 - Protective Agents
N-(3-AMINOPHENYL)-2-METHOXYACETAMIDE
C7H13N3O2 (171.10077180000002)
(S)-2-Amino-4-methyl-1-((R)-2-methyloxiran-2-yl)pentan-1-one
2,2,4,5,5-PENTAMETHYL-3-IMIDAZOLINE-3-OXIDE-1-OXYL, FREE RADICAL
N-(2-PROPYNYL)-2,3-DIHYDROINDEN-1-AMINE
D002491 - Central Nervous System Agents > D018696 - Neuroprotective Agents D004791 - Enzyme Inhibitors > D008996 - Monoamine Oxidase Inhibitors D020011 - Protective Agents
3-Cyclohexyl-L-alanine
COVID info from PDB, Protein Data Bank Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS
N-[(5-ETHYL-1,3,4-OXADIAZOL-2-YL)METHYL]-N-ISOPROPYLAMINE
3-Piperidinecarboxylicacid,1-(1-methylethyl)-(9CI)
(2-ethylpiperidin-1-yl)acetic acid(SALTDATA: FREE)
(S)-3-Methyl-piperidine-3-carboxylic acid ethyl ester
5-((1-METHOXYPROPAN-2-YL)OXY)-1H-PYRAZOL-3-AMINE
C7H13N3O2 (171.10077180000002)
1-Carbamimidoylpiperidine-4-carboxylic acid
C7H13N3O2 (171.10077180000002)
Piperazine, 1-(2-amino-1,1-dimethylethyl)-4-methyl- (8CI)
2-Piperidinecarboxylic acid,1-(1-methylethyl)-,(2R)-(9CI)
(1R,2R)-2-Amino-cyclohexanecarboxylic acid ethyl ester
(R)-CARBONOCHLORIDICACID1-AZABICYCLO[2.2.2]OCT-3-YLESTER
Trimethyl-[3-(prop-2-enoylamino)propyl]azanium
C9H19N2O+ (171.14973039999998)
Tert-butyl 2-cyano-2-methylhydrazinecarboxylate
C7H13N3O2 (171.10077180000002)
9-Oxononanoate
An aldehydic acid anion that is the conjugate base of 9-oxononanoic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.
fatty acid anion 10:0
Any saturated fatty acid anion containing 10 carbons. Formed by deprotonation of the carboxylic acid moiety. Major species at pH 7.3.
1-methyl-decylamine
{"Ingredient_id": "HBIN002798","Ingredient_name": "1-methyl-decylamine","Alias": "NA","Ingredient_formula": "C11H25N","Ingredient_Smile": "CCCCCCCCCC(C)N","Ingredient_weight": "171.32 g/mol","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "35123","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "114476","DrugBank_id": "NA"}
6-amino-6,7,8,9-tetrahydro-3h-1,4-diazonine-2,5-diol
C7H13N3O2 (171.10077180000002)
(1-carbamimidoylpyrrolidin-2-yl)acetic acid
C7H13N3O2 (171.10077180000002)
[(2r)-1-carbamimidoylpyrrolidin-2-yl]acetic acid
C7H13N3O2 (171.10077180000002)